Listed

BioNexus Gene Lab Corp

BGLCNasdaqCIK 1737523HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$76.2k, Q2 FY2026
Operating income−$282.4k, Q2 FY2026
Net income−$286.5k, Q2 FY2026
BioNexus Gene Lab Corp, income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$k2,554Revenue, Q3 FY2023, three months to 2023-09-30$2.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure2,273Revenue, Q4 FY2023, three months to 2023-12-31$2.3m. XBRL concept us-gaap:Revenues. 10-K filed 2025-04-15, accession 0001477932-25-002725. Derived: 12-month figure less the 9-month figure.Report this figure2,382Revenue, Q1 FY2024, three months to 2024-03-31$2.4m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure1,975Revenue, Q2 FY2024, three months to 2024-06-30$2.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure2,630Revenue, Q3 FY2024, three months to 2024-09-30$2.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure2,524Revenue, Q4 FY2024, three months to 2024-12-31$2.5m. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure2,137Revenue, Q1 FY2025, three months to 2025-03-31$2.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure2,260Revenue, Q2 FY2025, three months to 2025-06-30$2.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure2,544Revenue, Q3 FY2025, three months to 2025-09-30$2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure484Revenue, Q4 FY2025, three months to 2025-12-31$483.8k. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure22.8Revenue, Q1 FY2026, three months to 2026-03-31$22.8k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure76.2Revenue, Q2 FY2026, three months to 2026-06-30$76.2k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Cost of revenue$k2,199Cost of revenue, Q3 FY2023, three months to 2023-09-30$2.2m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure2,007Cost of revenue, Q4 FY2023, three months to 2023-12-31$2.0m. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2025-04-15, accession 0001477932-25-002725. Derived: 12-month figure less the 9-month figure.Report this figure2,017Cost of revenue, Q1 FY2024, three months to 2024-03-31$2.0m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure1,686Cost of revenue, Q2 FY2024, three months to 2024-06-30$1.7m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure2,304Cost of revenue, Q3 FY2024, three months to 2024-09-30$2.3m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure2,215Cost of revenue, Q4 FY2024, three months to 2024-12-31$2.2m. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure1,794Cost of revenue, Q1 FY2025, three months to 2025-03-31$1.8m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure1,892Cost of revenue, Q2 FY2025, three months to 2025-06-30$1.9m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure2,166Cost of revenue, Q3 FY2025, three months to 2025-09-30$2.2m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure488Cost of revenue, Q4 FY2025, three months to 2025-12-31$487.7k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure23.6Cost of revenue, Q1 FY2026, three months to 2026-03-31$23.6k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure63.2Cost of revenue, Q2 FY2026, three months to 2026-06-30$63.2k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Gross profit$k354Gross profit, Q3 FY2023, three months to 2023-09-30$354.3k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure267Gross profit, Q4 FY2023, three months to 2023-12-31$266.6k. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-04-15, accession 0001477932-25-002725. Derived: 12-month figure less the 9-month figure.Report this figure365Gross profit, Q1 FY2024, three months to 2024-03-31$365.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure289Gross profit, Q2 FY2024, three months to 2024-06-30$288.7k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure327Gross profit, Q3 FY2024, three months to 2024-09-30$326.5k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure309Gross profit, Q4 FY2024, three months to 2024-12-31$309.2k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure343Gross profit, Q1 FY2025, three months to 2025-03-31$343.5k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure368Gross profit, Q2 FY2025, three months to 2025-06-30$368.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure378Gross profit, Q3 FY2025, three months to 2025-09-30$377.7k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure(4.0)Gross profit, Q4 FY2025, three months to 2025-12-31−$4.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure(0.8)Gross profit, Q1 FY2026, three months to 2026-03-31−$790. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure13.0Gross profit, Q2 FY2026, three months to 2026-06-30$13.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Research and development$knot reportednot reported11.5Research and development, Q1 FY2024, three months to 2024-03-31$11.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure8.2Research and development, Q2 FY2024, three months to 2024-06-30$8.2k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure10.4Research and development, Q3 FY2024, three months to 2024-09-30$10.4k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure17.4Research and development, Q4 FY2024, three months to 2024-12-31$17.4k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure12.1Research and development, Q1 FY2025, three months to 2025-03-31$12.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure12.6Research and development, Q2 FY2025, three months to 2025-06-30$12.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure14.9Research and development, Q3 FY2025, three months to 2025-09-30$14.9k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure11.1Research and development, Q4 FY2025, three months to 2025-12-31$11.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure14.5Research and development, Q1 FY2026, three months to 2026-03-31$14.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure13.7Research and development, Q2 FY2026, three months to 2026-06-30$13.7k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Operating income$k(2,529)Operating income, Q3 FY2023, three months to 2023-09-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure258Operating income, Q4 FY2023, three months to 2023-12-31$257.8k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-04-15, accession 0001477932-25-002725. Derived: 12-month figure less the 9-month figure.Report this figure(79.0)Operating income, Q1 FY2024, three months to 2024-03-31−$79.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure259Operating income, Q2 FY2024, three months to 2024-06-30$259.2k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure(1,338)Operating income, Q3 FY2024, three months to 2024-09-30−$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure(416)Operating income, Q4 FY2024, three months to 2024-12-31−$416.2k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure(618)Operating income, Q1 FY2025, three months to 2025-03-31−$618.4k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure(611)Operating income, Q2 FY2025, three months to 2025-06-30−$611.3k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure(703)Operating income, Q3 FY2025, three months to 2025-09-30−$702.5k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure(1,033)Operating income, Q4 FY2025, three months to 2025-12-31−$1.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure(540)Operating income, Q1 FY2026, three months to 2026-03-31−$540.5k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure(282)Operating income, Q2 FY2026, three months to 2026-06-30−$282.4k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Interest expense$k4.3Interest expense, Q3 FY2023, three months to 2023-09-30$4.3k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure4.2Interest expense, Q4 FY2023, three months to 2023-12-31$4.2k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-04-16, accession 0001477932-24-002151. Derived: 12-month figure less the 9-month figure.Report this figure4.7Interest expense, Q1 FY2024, three months to 2024-03-31$4.7k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-15, accession 0001477932-24-002941.Report this figure4.5Interest expense, Q2 FY2024, three months to 2024-06-30$4.5k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-08-14, accession 0001477932-24-004792. Derived: 6-month figure less the 3-month figure.Report this figure6.2Interest expense, Q3 FY2024, three months to 2024-09-30$6.2k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$k76.4Income tax, Q3 FY2023, three months to 2023-09-30$76.4k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure(97.9)Income tax, Q4 FY2023, three months to 2023-12-31−$97.9k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-04-15, accession 0001477932-25-002725. Derived: 12-month figure less the 9-month figure.Report this figure(20.1)Income tax, Q1 FY2024, three months to 2024-03-31−$20.1k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure55.6Income tax, Q2 FY2024, three months to 2024-06-30$55.6k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure1.6Income tax, Q3 FY2024, three months to 2024-09-30$1.6k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure(80.7)Income tax, Q4 FY2024, three months to 2024-12-31−$80.7k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Net income$k(2,609)Net income, Q3 FY2023, three months to 2023-09-30−$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure308Net income, Q4 FY2023, three months to 2023-12-31$308.5k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-04-15, accession 0001477932-25-002725. Derived: 12-month figure less the 9-month figure.Report this figure(104)Net income, Q1 FY2024, three months to 2024-03-31−$103.8k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure199Net income, Q2 FY2024, three months to 2024-06-30$199.1k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure(1,345)Net income, Q3 FY2024, three months to 2024-09-30−$1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure(348)Net income, Q4 FY2024, three months to 2024-12-31−$348.3k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure(623)Net income, Q1 FY2025, three months to 2025-03-31−$623.3k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure(616)Net income, Q2 FY2025, three months to 2025-06-30−$616.2k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure(709)Net income, Q3 FY2025, three months to 2025-09-30−$709.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure(1,036)Net income, Q4 FY2025, three months to 2025-12-31−$1.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure(544)Net income, Q1 FY2026, three months to 2026-03-31−$543.6k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure(286)Net income, Q2 FY2026, three months to 2026-06-30−$286.5k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Diluted EPS$ per sharenot reportednot reported(0.01)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure0.11Diluted EPS, Q2 FY2024, three months to 2024-06-30$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure(0.75)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figurenot reported(0.35)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure(0.34)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure(0.40)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figurenot reported(0.23)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure(0.12)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure

Balance sheet

Cash and equivalents$1.2m, Q2 FY2026
Shareholders' equity$7.8m, Q2 FY2026
BioNexus Gene Lab Corp, balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m4.7Cash and equivalents, Q3 FY2023, at 2023-09-30$4.7m. XBRL concept us-gaap:Cash. 10-Q/A filed 2024-03-26, accession 0001477932-24-001468.Report this figure2.6Cash and equivalents, FY2023, at 2023-12-31$2.6m. XBRL concept us-gaap:Cash. 10-Q filed 2024-05-15, accession 0001477932-24-002941.Report this figure2.5Cash and equivalents, Q1 FY2024, at 2024-03-31$2.5m. XBRL concept us-gaap:Cash. 10-Q filed 2024-05-15, accession 0001477932-24-002941.Report this figurenot reportednot reported2.9Cash and equivalents, FY2024, at 2024-12-31$2.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-04-14, accession 0001477932-26-002218.Report this figurenot reportednot reportednot reported2.4Cash and equivalents, FY2025, at 2025-12-31$2.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figurenot reported1.2Cash and equivalents, Q2 FY2026, at 2026-06-30$1.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Current assets$m8.3Current assets, Q3 FY2023, at 2023-09-30$8.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q/A filed 2024-03-26, accession 0001477932-24-001468.Report this figure8.0Current assets, FY2023, at 2023-12-31$8.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-04-15, accession 0001477932-25-002725.Report this figure7.9Current assets, Q1 FY2024, at 2024-03-31$7.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-15, accession 0001477932-24-002941.Report this figure7.8Current assets, Q2 FY2024, at 2024-06-30$7.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0001477932-24-004792.Report this figure7.0Current assets, Q3 FY2024, at 2024-09-30$7.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure7.4Current assets, FY2024, at 2024-12-31$7.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-04-14, accession 0001477932-26-002218.Report this figure6.5Current assets, Q1 FY2025, at 2025-03-31$6.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure6.4Current assets, Q2 FY2025, at 2025-06-30$6.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure5.6Current assets, Q3 FY2025, at 2025-09-30$5.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure5.4Current assets, FY2025, at 2025-12-31$5.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure5.2Current assets, Q1 FY2026, at 2026-03-31$5.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure4.9Current assets, Q2 FY2026, at 2026-06-30$4.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Total assets$m11.5Total assets, Q3 FY2023, at 2023-09-30$11.5m. XBRL concept us-gaap:Assets. 10-Q/A filed 2024-03-26, accession 0001477932-24-001468.Report this figure11.4Total assets, FY2023, at 2023-12-31$11.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-04-15, accession 0001477932-25-002725.Report this figure11.2Total assets, Q1 FY2024, at 2024-03-31$11.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-15, accession 0001477932-24-002941.Report this figure11.1Total assets, Q2 FY2024, at 2024-06-30$11.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0001477932-24-004792.Report this figure11.0Total assets, Q3 FY2024, at 2024-09-30$11.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure10.4Total assets, FY2024, at 2024-12-31$10.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-04-14, accession 0001477932-26-002218.Report this figure9.5Total assets, Q1 FY2025, at 2025-03-31$9.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure9.4Total assets, Q2 FY2025, at 2025-06-30$9.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure7.6Total assets, Q3 FY2025, at 2025-09-30$7.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure9.3Total assets, FY2025, at 2025-12-31$9.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure9.0Total assets, Q1 FY2026, at 2026-03-31$9.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure8.7Total assets, Q2 FY2026, at 2026-06-30$8.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Current liabilities$m1.6Current liabilities, Q3 FY2023, at 2023-09-30$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q/A filed 2024-03-26, accession 0001477932-24-001468.Report this figure1.6Current liabilities, FY2023, at 2023-12-31$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-04-15, accession 0001477932-25-002725.Report this figure1.7Current liabilities, Q1 FY2024, at 2024-03-31$1.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-15, accession 0001477932-24-002941.Report this figure1.4Current liabilities, Q2 FY2024, at 2024-06-30$1.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0001477932-24-004792.Report this figure1.4Current liabilities, Q3 FY2024, at 2024-09-30$1.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure2.0Current liabilities, FY2024, at 2024-12-31$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-04-14, accession 0001477932-26-002218.Report this figure1.6Current liabilities, Q1 FY2025, at 2025-03-31$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure1.8Current liabilities, Q2 FY2025, at 2025-06-30$1.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure0.7Current liabilities, Q3 FY2025, at 2025-09-30$678.0k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure0.5Current liabilities, FY2025, at 2025-12-31$521.0k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure0.8Current liabilities, Q1 FY2026, at 2026-03-31$796.5k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure0.8Current liabilities, Q2 FY2026, at 2026-06-30$812.9k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Total liabilities$m1.8Total liabilities, Q3 FY2023, at 2023-09-30$1.8m. XBRL concept us-gaap:Liabilities. 10-Q/A filed 2024-03-26, accession 0001477932-24-001468.Report this figure1.7Total liabilities, FY2023, at 2023-12-31$1.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-04-15, accession 0001477932-25-002725.Report this figure1.8Total liabilities, Q1 FY2024, at 2024-03-31$1.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-15, accession 0001477932-24-002941.Report this figure1.6Total liabilities, Q2 FY2024, at 2024-06-30$1.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0001477932-24-004792.Report this figure1.6Total liabilities, Q3 FY2024, at 2024-09-30$1.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure2.1Total liabilities, FY2024, at 2024-12-31$2.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-04-14, accession 0001477932-26-002218.Report this figure1.7Total liabilities, Q1 FY2025, at 2025-03-31$1.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure1.9Total liabilities, Q2 FY2025, at 2025-06-30$1.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure0.8Total liabilities, Q3 FY2025, at 2025-09-30$805.0k. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure0.6Total liabilities, FY2025, at 2025-12-31$637.9k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure0.9Total liabilities, Q1 FY2026, at 2026-03-31$946.9k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure0.9Total liabilities, Q2 FY2026, at 2026-06-30$948.0k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure
Shareholders' equity$m9.3Shareholders' equity, Q3 FY2023, at 2023-09-30$9.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-15, accession 0001477932-24-007332.Report this figure9.7Shareholders' equity, FY2023, at 2023-12-31$9.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-04-14, accession 0001477932-26-002218.Report this figure9.3Shareholders' equity, Q1 FY2024, at 2024-03-31$9.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure9.5Shareholders' equity, Q2 FY2024, at 2024-06-30$9.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure9.4Shareholders' equity, Q3 FY2024, at 2024-09-30$9.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure8.3Shareholders' equity, FY2024, at 2024-12-31$8.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure7.8Shareholders' equity, Q1 FY2025, at 2025-03-31$7.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure7.5Shareholders' equity, Q2 FY2025, at 2025-06-30$7.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure6.8Shareholders' equity, Q3 FY2025, at 2025-09-30$6.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure8.6Shareholders' equity, FY2025, at 2025-12-31$8.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure8.1Shareholders' equity, Q1 FY2026, at 2026-03-31$8.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure7.8Shareholders' equity, Q2 FY2026, at 2026-06-30$7.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure

Cash flow

Operating cash flow−$422.5k, Q2 FY2026
Capital expenditure$250, Q2 FY2026
BioNexus Gene Lab Corp, cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(899)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$899.3k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-15, accession 0001477932-24-007332. Derived: 9-month figure less the 6-month figure.Report this figure(783)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$782.5k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-04-15, accession 0001477932-25-002725. Derived: 12-month figure less the 9-month figure.Report this figure(37.2)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$37.2k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure(672)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$672.3k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-18, accession 0001477932-25-006023. Derived: 6-month figure less the 3-month figure.Report this figure(1,603)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001477932-25-008343. Derived: 9-month figure less the 6-month figure.Report this figure219Operating cash flow, Q4 FY2024, three months to 2024-12-31$219.2k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure(824)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$824.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure(738)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$737.9k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001477932-26-005093. Derived: 6-month figure less the 3-month figure.Report this figure(1,237)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001477932-25-008343. Derived: 9-month figure less the 6-month figure.Report this figure961Operating cash flow, Q4 FY2025, three months to 2025-12-31$961.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure(148)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$147.7k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure(422)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$422.5k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001477932-26-005093. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k134Capital expenditure, Q3 FY2023, three months to 2023-09-30$134.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-15, accession 0001477932-24-007332. Derived: 9-month figure less the 6-month figure.Report this figure0.9Capital expenditure, Q4 FY2023, three months to 2023-12-31$937. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-04-15, accession 0001477932-25-002725. Derived: 12-month figure less the 9-month figure.Report this figure21.9Capital expenditure, Q1 FY2024, three months to 2024-03-31$21.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure1.8Capital expenditure, Q2 FY2024, three months to 2024-06-30$1.8k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-18, accession 0001477932-25-006023. Derived: 6-month figure less the 3-month figure.Report this figure199Capital expenditure, Q3 FY2024, three months to 2024-09-30$199.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001477932-25-008343. Derived: 9-month figure less the 6-month figure.Report this figure4.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure9.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$9.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure21.5Capital expenditure, Q2 FY2025, three months to 2025-06-30$21.5k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001477932-26-005093. Derived: 6-month figure less the 3-month figure.Report this figure5.5Capital expenditure, Q3 FY2025, three months to 2025-09-30$5.5k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001477932-25-008343. Derived: 9-month figure less the 6-month figure.Report this figure1.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$977. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-04-14, accession 0001477932-26-002218. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2026, three months to 2026-03-31$325. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure0.3Capital expenditure, Q2 FY2026, three months to 2026-06-30$250. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001477932-26-005093. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)2.42m, Q2 FY2026
BioNexus Gene Lab Corp, shares, quarterly
Line itemUnitQ1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares17.7Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3117,667,663 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001477932-25-003821.Report this figure1.8Diluted shares (weighted), Q2 FY2024, three months to 2024-06-301,766,766 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-18, accession 0001477932-25-006023.Report this figure1.8Diluted shares (weighted), Q3 FY2024, three months to 2024-09-301,796,766 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure1.8Diluted shares (weighted), Q1 FY2025, three months to 2025-03-311,796,766 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure1.8Diluted shares (weighted), Q2 FY2025, three months to 2025-06-301,796,597 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure1.8Diluted shares (weighted), Q3 FY2025, three months to 2025-09-301,796,597 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001477932-25-008343.Report this figure2.4Diluted shares (weighted), Q1 FY2026, three months to 2026-03-312,417,314 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001477932-26-003242.Report this figure2.4Diluted shares (weighted), Q2 FY2026, three months to 2026-06-302,417,314 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure

Shares outstanding: 2.93mShares outstanding, period not labelled, at 2026-08-142,933,442 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001477932-26-005093.Report this figure at Aug 14, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.